| For: | Liu D, Shi Y, Chen H, Nisar MA, Jabara N, Langwinski N, Mattson S, Nagaoka K, Bai X, Lu S, Huang CK. Molecular profiling reveals potential targets in cholangiocarcinoma. World J Gastroenterol 2023; 29(25): 4053-4071 [PMID: 37476584 DOI: 10.3748/wjg.v29.i25.4053] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v29/i25/4053.htm |
| Number | Citing Articles |
| 1 |
Mei Feng, Hong Liu, Lu Zheng, Yang Liu, Hao Zhuang, Hao Xu, Tingting Zhang, Zhen Wu, Xiaolong Qian, Huikai Li, Tengfei Xiao, Yisheng Pan, Shaokun Shu, Ning Zhang. Genome-wide screenings identify BAP1 as a synthetic-lethality target with CDK4/6 inhibitors. Science Advances 2026; 12(3) doi: 10.1126/sciadv.aeb4348
|
| 2 |
Cheerapinya Taebprakhon, Supannika Sorin, Kullanat Khawkhiaw, Chatchai Phoomak, Wunchana Seubwai, Sopit Wongkham, Charupong Saengboonmee. Pro-Tumorigenic Roles of Cyclin Dependent Kinase 2 and its Associated Cyclins in Cholangiocarcinoma Progression under High Glucose Condition. Archives of Medical Research 2026; 57(3): 103383 doi: 10.1016/j.arcmed.2026.103383
|
| 3 |
Nikola Hadzi-Petrushev, Radoslav Stojchevski, Anastasija Jakimovska, Mimoza Stamenkovska, Slavica Josifovska, Aleksandar Stamatoski, Iliyana Sazdova, Ramadan Sopi, Andre Kamkin, Hristo Gagov, Mitko Mladenov, Dimiter Avtanski. GLUT5-overexpression-related tumorigenic implications. Molecular Medicine 2024; 30(1) doi: 10.1186/s10020-024-00879-8
|
| 4 |
Xiaoyan Sun, Xiaofang Zhao, Senyan Wang, Qi Liu, Wenjuan Wei, Jing Xu, Hongyang Wang, Wen Yang. The pathological significance and potential mechanism of ACLY in cholangiocarcinoma. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1477267
|
